Mird237 Better Fixed <2025>

—by every metric: lower toxicity, higher tumor control, rigorous uncertainty tracking, and microscale relevance. If you are still using organ-level, static, phantom-based dosimetry, you are practicing outdated medicine. The evidence is in, the tools are ready, and the regulatory tide has turned.

Every “better” implies a predecessor. In the case of mird237, the antecedent is not a single failure but a family of compromises: legacy systems (e.g., mird189, mird212) that prioritized either raw throughput without stability, or stability without adaptability. These earlier versions exhibited: mird237 better

In anonymous surveys of 1,200 engineers who switched from prior versions to mird237: —by every metric: lower toxicity, higher tumor control,